Literature DB >> 20127359

Expression of metalloproteases and their inhibitors by tumor and stromal cells in ductal carcinoma in situ of the breast and their relationship with microinvasive events.

L O González1, S González-Reyes, S Junquera, L Marín, L González, J M Del Casar, J M González, Francisco Vizoso.   

Abstract

AIMS: This study aimed to investigate the expression of matrix metalloproteases (MMPs) and their inhibitors (TIMPs) in ductal carcinoma in situ (DCIS).
METHODS: We used inmunohistochemistry to compare the expression of MMPs and TIMPs in tumor or stromal cells for 50 pure DCIS and 12 DCIS with microinvasive foci.
RESULTS: Score values for collagenase-1 (MMP-1), membrane type 1 MMP (MMP-14), and TIMP-1, were significantly higher in pure DCIS than in DCIS with microinvasive foci, whereas stromalysin-3 (MMP-11) expression was significantly higher in DCIS with microinvasive foci. Both fibroblasts and mononuclear inflammatory cells (MICs) surrounding pure DCIS showed more frequently expression of MMP-1, MMP-14, and TIMP-3, whereas MMP-11 expression was more frequent in MICs of microinvasive tumors. MICs of microinvasive foci more frequently showed the expression of gelatinase A (MMP-2), MMP-11, collagenase-3 (MMP-13), and TIMP-1, than MICs surrounding pure DCIS; whereas peri-ductal MICs and fibroblasts from pure DCIS expressed TIMP-3 more commonly than these cells at microinvasive foci.
CONCLUSIONS: There are significant differences in the expression of MMPs and TIMPs, so in tumor cells and stromal cells, between pure DCIS and DCIS with microinvasive foci. Therefore, these staining patterns might display potential applications as biological markers, such as in evaluating microinvasion in resection specimens of breast tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127359     DOI: 10.1007/s00432-010-0782-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  42 in total

1.  Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis.

Authors:  A H Baker; A B Zaltsman; S J George; A C Newby
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

2.  Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors.

Authors:  Anja Wild; Annette Ramaswamy; Peter Langer; Ilhan Celik; Volker Fendrich; Brunhilde Chaloupka; Babette Simon; Detlef K Bartsch
Journal:  J Clin Endocrinol Metab       Date:  2003-03       Impact factor: 5.958

Review 3.  The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the "protease-centered" hypothesis.

Authors:  Yan-Gao Man; Qing-Xiang Amy Sang
Journal:  Exp Cell Res       Date:  2004-12-10       Impact factor: 3.905

4.  Matrix metalloproteinases: biologic activity and clinical implications.

Authors:  A R Nelson; B Fingleton; M L Rothenberg; L M Matrisian
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

5.  Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3.

Authors:  Matti Ahonen; Risto Ala-Aho; Andrew H Baker; Sarah J George; Reidar Grénman; Ulpu Saarialho-Kere; Veli-Matti Kähäri
Journal:  Mol Ther       Date:  2002-06       Impact factor: 11.454

6.  Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers.

Authors:  K E Bachman; J G Herman; P G Corn; A Merlo; J F Costello; W K Cavenee; S B Baylin; J R Graff
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

7.  Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology.

Authors:  M Polette; C Clavel; M Cockett; S Girod de Bentzmann; G Murphy; P Birembaut
Journal:  Invasion Metastasis       Date:  1993

8.  Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Authors:  Hee Jung Kim; Chan-il Park; Byeong Woo Park; Hy-de Lee; Woo Hee Jung
Journal:  Yonsei Med J       Date:  2006-06-30       Impact factor: 2.759

9.  Biochemical characterization of human collagenase-3.

Authors:  V Knäuper; C López-Otin; B Smith; G Knight; G Murphy
Journal:  J Biol Chem       Date:  1996-01-19       Impact factor: 5.157

10.  Molecular markers in ductal carcinoma in situ of the breast.

Authors:  Dale Porter; Jaana Lahti-Domenici; Aparna Keshaviah; Young Kyung Bae; Pedram Argani; Jeffrey Marks; Andrea Richardson; Amiel Cooper; Robert Strausberg; Gregory J Riggins; Stuart Schnitt; Edward Gabrielson; Rebecca Gelman; Kornelia Polyak
Journal:  Mol Cancer Res       Date:  2003-03       Impact factor: 5.852

View more
  5 in total

Review 1.  A new paradigm for mechanobiological mechanisms in tumor metastasis.

Authors:  Peter A Torzilli; Jonathan W Bourne; Tessa Cigler; C Theresa Vincent
Journal:  Semin Cancer Biol       Date:  2012-05-18       Impact factor: 15.707

2.  Matrix metalloproteinase 2 overexpression and prognosis in colorectal cancer: a meta-analysis.

Authors:  Mumu Shi; Bo Yu; Hongguo Gao; Jingwen Mu; Changwei Ji
Journal:  Mol Biol Rep       Date:  2012-11-27       Impact factor: 2.316

Review 3.  Collagen as a double-edged sword in tumor progression.

Authors:  Min Fang; Jingping Yuan; Chunwei Peng; Yan Li
Journal:  Tumour Biol       Date:  2013-12-15

4.  MMP1 and MMP11 Expression in Peripheral Blood Mononuclear Cells upon Their Interaction with Breast Cancer Cells and Fibroblasts.

Authors:  Noemi Eiro; Sandra Cid; Nuria Aguado; María Fraile; Nagore de Pablo; Berta Fernández; Francisco Domínguez; Luis O González; Francisco J Vizoso
Journal:  Int J Mol Sci       Date:  2020-12-31       Impact factor: 5.923

Review 5.  Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis.

Authors:  Kylie L Gorringe; Stephen B Fox
Journal:  Front Oncol       Date:  2017-10-23       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.